SCHEMBL14627554

SCHEMBL14627554

CNc1cc(F)ccc1C(=O)CSOC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.36
MAPT P10636 5/20 0.35
KMT2A Q03164 3/20 0.35
HTT P42858 3/20 0.35
MEN1 O00255 2/20 0.35
IKBKB O14920 1/20 0.35
CLCN2 P51788 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 1/20 0.34
KDM4E B2RXH2 2/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
POLB P06746 1/20 0.34
ATM Q13315 1/20 0.34
TP53 P04637 2/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9722911 0.84 IKBKB (0.38) MAPTKMT2AHTTMEN1IKBKB
SCHEMBL10481312 0.81 ALDH1A1 (0.38) MAPTKMT2AIKBKBCLCN2SMN1; SMN2
SCHEMBL27731731 0.79 HSP90AB1 (0.43) MAPTKMT2AHTTMEN1IKBKB
SCHEMBL9722967 0.77 ALDH1A1 (0.42) MAPTHTTIKBKBCLCN2NPC1
SCHEMBL9744146 0.77 KDM4E (0.58) FFAR4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3810854 0.76 CLCN2 (0.52) MAPTKMT2AMEN1IKBKBCLCN2
SCHEMBL9722960 0.74 MRGPRX1 (0.37) MAPTKMT2AIKBKBCLCN2SMN1; SMN2
SCHEMBL9722931 0.73 CES2 (0.44) HTTIKBKBCLCN2CES2CES1
SCHEMBL6535624 0.72 IKBKB (0.36) MAPTHTTIKBKBCLCN2SMN1; SMN2
SCHEMBL10631588 0.72 KMT2A (0.38) MAPTKMT2AIKBKBCLCN2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010676-A1 Stereospecific enrichment of heterocyclic enantiomers R.T. ALAMO VENTURES I, LLC 2007-01-11 US disclosed
US-20070010552-A1 Fluorinated heterocyclic compounds and methods of synthesis R.T. ALAMO VENTURES I, LLC 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010676-A1 Stereospecific enrichment of heterocyclic enantiomers CBR3, CBR1, QDPR FFAR4 1056/4885MAPT 4853/4885KMT2A 3308/4885
US-20070010552-A1 Fluorinated heterocyclic compounds and methods of synthesis FDPS, PFAS, AFF4 FFAR4 1268/4885MAPT 4164/4885KMT2A 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.